Page 42 - ARNM-2-3

Advances in Radiotherapy
& Nuclear Medicine Molecular imaging of lung cancer

J Nucl Med Technol. 2005;33(3):69-74. intra-individual comparison of biodistribution and tumor
uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer
52. Zhu J, Pan F, Cai H, et al. Positron emission tomography
imaging of lung cancer: An overview of alternative patients. Eur J Nucl Med Mol Imaging. 2021;48(13):4377-4385.
positron emission tomography tracers beyond F18 doi: 10.1007/s00259-021-05307-1
fluorodeoxyglucose. Front Med (Lausanne). 2022;9:945602.
64. Chalkidou A, Landau DB, Odell EW, Cornelius VR,
doi: 10.3389/fmed.2022.945602 O’Doherty MJ, Marsden PK. Correlation between Ki-67
53. Farwell MD, Pryma DA, Mankoff DA. PET/CT imaging in immunohistochemistry and 18F-fluorothymidine uptake in
cancer: Current applications and future directions. Cancer. patients with cancer: A systematic review and meta-analysis.
2014;120(22):3433-3445. Eur J Cancer. 2012;48(18):3499-3513.
doi: 10.1002/cncr.28860 doi: 10.1016/j.ejca.2012.05.001
54. Sanchez Salmon A, Barandela Salgado J, Ruibal Morell A. 65. Sanghera B, Wong WL, Sonoda LI, et al. FLT PET-CT
PET in abdominal pathology: Advantages and limitations. in evaluation of treatment response. Indian J Nucl Med.
Abdom Imaging. 2006;31(2):174-181. 2014;29(2):65-73.
doi: 10.1007/s00261-005-0384-7 doi: 10.4103/0972-3919.130274
55. Ambrosini V, Nicolini S, Caroli P, et al. PET/CT imaging in 66. Wang FL, Tan YY, Gu XM, et al. Comparison of positron
different types of lung cancer: An overview. Eur J Radiol. emission tomography using 2-[18F]-fluoro-2-deoxy-D-
2012;81(5):988-1001. glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung
Cancer Imaging. Chin Med J (Engl). 2016;129(24):2926-2935.
doi: 10.1016/j.ejrad.2011.03.020
doi: 10.4103/0366-6999.195468
56. Krarup MMK, Fischer BM, Christensen TN. New PET
tracers: Current knowledge and perspectives in lung cancer. 67. Xu X, Nie L, Yao Y, Tu Y, Zhou J. Pre-radiotherapy assessment
Semin Nucl Med. 2022;52(6):781-796. of non-small cell lung cancer with 18F-FLT PET/CT or 18F-
FDG PET/CT. Int J Clin Exp Med. 2016;9:9252-9260.
doi: 10.1053/j.semnuclmed.2022.05.002
68. Tian J, Yang X, Yu L, et al. A multicenter clinical trial on
57. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG- the diagnostic value of dual-tracer PET/CT in pulmonary
PET to diagnose lung cancer in areas with infectious lung
disease: A meta-analysis. JAMA. 2014;312(12):1227-1236. lesions using 3’-deoxy-3’-18F-fluorothymidine and 18F-
FDG. J Nucl Med. 2008;49(2):186-194.
doi: 10.1001/jama.2014.11488
doi: 10.2967/jnumed.107.044966
58. Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/
CT imaging in oncology. Ann Saudi Med. 2011;31(1):3-13. 69. Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W.
ImmunoPET: Concept, design, and applications. Chem Rev.
doi: 10.4103/0256-4947.75771 2020;120(8):3787-3851.
59. Borgonje PE, Andrews LM, Herder GJM, de Klerk JMH. doi: 10.1021/acs.chemrev.9b00738
Performance and prospects of [(68)Ga]Ga-FAPI PET/CT
scans in lung cancer. Cancers (Basel). 2022;14(22):5566. 70. De Feo MS, Pontico M, Frantellizzi V, Corica F, De
Cristofaro F, De Vincentis G. 89Zr-PET imaging in humans:
doi: 10.3390/cancers14225566 A systematic review. Clin Trans Imaging. 2021;10(1):23-36.
60. Huang R, Pu Y, Huang S, et al. FAPI-PET/CT in cancer doi: 10.1007/s40336-021-00462-9
imaging: A potential novel molecule of the century. Front
Oncol. 2022;12:854658. 71. Dolled-Filhart M, Roach C, Toland G, et al. Development of
a companion diagnostic for pembrolizumab in non-small cell
doi: 10.3389/fonc.2022.854658 lung cancer using immunohistochemistry for programmed
61. Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. death ligand-1. Arch Pathol Lab Med. 2016;140(11):1243-1249.
Understanding fibroblast activation protein (FAP): doi: 10.5858/arpa.2015-0542-OA
Substrates, activities, expression and targeting for cancer
therapy. Proteomics Clin Appl. 2014;8(5-6):454-463. 72. Walker R, Deppen S, Smith G, et al. 68Ga-DOTATATE PET/
CT imaging of indeterminate pulmonary nodules and lung
doi: 10.1002/prca.201300095 cancer. PLoS One. 2017;12(2):e0171301.
62. Kratochwil C, Flechsig P, Lindner T, et al. (68)Ga-FAPI PET/ doi: 10.1371/journal.pone.0171301
CT: Tracer uptake in 28 different kinds of cancer. J Nucl Med.
2019;60(6):801-805. 73. Hu X, Li D, Wang R, Wang P, Cai J. Comparison of the
application of 18F-FDG and 68Ga-DOTATATE PET/CT
doi: 10.2967/jnumed.119.227967
in neuroendocrine tumors: A retrospective study. Medicine
63. Giesel FL, Kratochwil C, Schlittenhardt J, et al. Head-to-head (Baltimore). 2023;102(19):e33726.

Volume 2 Issue 3 (2024) 10 doi: 10.36922/arnm.4173